Sponsors (2)
The bill could improve early detection and prevention of esophageal cancer for higher‑risk people and give Congress better FEHBP spending data, but it risks higher screening costs, potential overdiagnosis and equity concerns while delivering only indirect, report‑based changes to care access.
People at higher risk (patients with chronic conditions, seniors/retirees, and federal enrollees) could get earlier detection and fewer future esophageal cancers because the bill encourages awareness, targeted screening, and prevention/treatment of Barrett’s esophagus and requires a report identifying FEHBP screening gaps.
Clinicians and health systems may adopt more targeted, guideline-consistent use of endoscopy for higher-risk people, improving screening efficiency and potentially reducing unnecessary procedures overall.
Federal oversight will improve because Congress will receive GAO data on total FEHBP esophageal cancer spending, enabling identification of cost drivers and potential policy changes to control program costs.
Many people and taxpayers could face higher health care spending because expanded awareness and screening (more endoscopies) can increase utilization and out-of-pocket and program costs.
Some patients (including seniors) could be harmed by overdiagnosis and unnecessary procedures if expanded screening finds lesions that would not progress, exposing them to procedural risks.
Because the bill primarily requires a report rather than funding or coverage changes, many federal enrollees may see limited or delayed direct benefits in access to screening or care.
Based on analysis of 3 sections of legislative text.
Requires GAO to report within one year on FEHBP esophageal cancer spending and whether high-risk enrollees receive guideline-consistent screening.
Requires the Government Accountability Office (GAO) to report to Congress within one year on esophageal cancer spending and screening practices under the Federal Employees Health Benefits Program (FEHBP). The bill also records congressional findings about rising esophageal cancer rates, lethality, and the role of early detection and screening for high-risk people. The report must estimate total FEHBP health-care spending for members diagnosed with esophageal cancer and evaluate how often FEHBP enrollees identified as high-risk receive screening consistent with established clinical guidelines.
Introduced May 19, 2025 by Gerald E. Connolly · Last progress June 9, 2026